Page last updated: 2024-09-04

moxifloxacin and rifampin

moxifloxacin has been researched along with rifampin in 253 studies

Compound Research Comparison

Studies (moxifloxacin)	Trials (moxifloxacin)	Recent Studies (post-2010) (moxifloxacin)	Studies (rifampin)	Trials (rifampin)	Recent Studies (post-2010) (rifampin)
3,157	552	1,690	20,468	1,499	6,552

Protein Interaction Comparison

Protein	Taxonomy	rifampin (IC50)
Polyunsaturated fatty acid lipoxygenase ALOX15	Oryctolagus cuniculus (rabbit)	2.949
Caspase-1	Homo sapiens (human)	8.319
Alpha-synuclein	Homo sapiens (human)	7.1
Enoyl-[acyl-carrier-protein] reductase [NADH]	Mycobacterium tuberculosis H37Rv	0.03
DNA-directed RNA polymerase subunit beta	Mycobacterium tuberculosis H37Rv	0.01
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	1.5
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	1.5

Research

Studies (253)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (0.79)	18.2507
2000's	60 (23.72)	29.6817
2010's	140 (55.34)	24.3611
2020's	51 (20.16)	2.80

Authors

Authors	Studies
Duewelhenke, N; Eysel, P; Krut, O	1
Frank, KL; Patel, R; Piper, KE; Reichert, EJ	1
Andries, K; Chauffour, A; Ibrahim, M; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S	1
Agarwal, V; Burman, W; Engle, M; Goldberg, S; Luo, CC; Peloquin, CA; Vernon, A; Weiner, M	1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F	1
Brémont, S; Courvalin, P; Damier-Piolle, L; Lambert, T; Magnet, S	1
Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L	1
Lombardo, F; Obach, RS; Waters, NJ	1
Cattoir, V; Nordmann, P; Poirel, L	1
del Pozo, JL; Mandrekar, JN; Patel, R; Rouse, MS; Sampedro, MF; Steckelberg, JM	1
Karlowsky, JA; Laing, NM; Zhanel, GG	1
Aarnoutse, RE; Boeree, MJ; Kibiki, GS; Kisanga, ER; van den Boogaard, J	1
Denis, O; Nguyen, HA; Struelens, MJ; Theunis, A; Tulkens, PM; Van Bambeke, F; Vergison, A	1
Chlipala, G; Krunic, A; Mo, S; Orjala, J	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Franzblau, SG; Kozikowski, AP; Lilienkampf, A; Pieroni, M; Wan, B; Wang, Y	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Chibale, K; Franzblau, SG; Guantai, EM; Gut, J; Hans, RH; Lategan, C; Rosenthal, PJ; Smith, PJ; Wan, B	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Angulo-Barturen, I; Beltrán, M; Cáceres, N; Cardona, PJ; García, JI; García-Bustos, JF; Rullas, J	1
Disratthakit, A; Doi, N	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Zhang, T	1
Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA	1
Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C	1
Khanna, A; Pareek, PK; Raj, VS; Rattan, A; Saini, KS; Sharma, P; Singh, H; Sood, R; Tarai, B; Upadhyay, DJ	1
Charnock, C; Franzblau, S; Gundersen, LL; Khoje, AD; Kulendrn, A; Wan, B	1
Chibale, K; Franzblau, SG; Gut, J; Hans, RH; Rosenthal, PJ; van Helden, PD; Wan, B; Wiid, IJ	1
Aguinaldo, MA; Chen, X; Cordell, GA; Decker, M; Franzblau, SG; Galvez, EV; Heilmann, J; Macabeo, AP; Vidar, WS; Wan, B	1
Franzblau, SG; Garcia, GA; Gill, SK; Jin, Y; Kirchhoff, PD; Showalter, HD; Wan, B	1
Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N	1
Cierpicki, T; Franzblau, SG; Garcia, GA; Gill, SK; Kirchhoff, PD; Peng, KW; Showalter, HD; Turbiak, AJ; Wan, B; Xu, H; Zhang, N	1
Chovatia, PT; Parekh, HH; Pathak, RB	1
Dulla, B; Franzblau, SG; Iqbal, J; Kapavarapu, R; Pal, M; Reiser, O; Wan, B	1
Barry, CE; Dartois, V	1
Ambady, A; Bandodkar, B; Bhat, J; Davies, G; Hameed, S; Hegde, N; Holdgate, G; Kumar, A; Madhavapeddi, P; McMiken, H; Murugan, K; Naik, M; Nandishaiah, R; Panda, M; Read, JA; Sambandamurthy, VK; Shinde, V; Shirude, PS; Venkatraman, J	1
Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J	1
Achar, V; Ambady, A; Awasthy, D; Bathula, C; Binda, C; Chatterji, M; Chiarelli, LR; Dhar, N; Dinesh, N; Ghorpade, SR; Gorai, G; Guptha, S; Hegde, N; Hosagrahara, V; Humnabadkar, V; Iyer, PS; Jatheendranath, S; Jena, LK; Kaur, P; Kavanagh, S; Koushik, K; Madhavapeddi, P; Mahadevaswamy, J; Manjrekar, P; Manjunatha, MR; McKinney, JD; McLaughlin, B; Naik, M; Narayan, A; Narayan, C; Narayanan, S; Neres, J; Panda, M; Panduga, V; Pasca, MR; Prabhakar, K; Ramachandran, V; Ravishankar, S; Reddy, J; Riccardi, G; Rudrapatna, S; Sambandamurthy, VK; Saralaya, R; Shanbhag, G; Shandil, R; Sharma, S; Signorino-Gelo, F; Tantry, SJ; Tommasi, R; Whiteaker, J	1
Cho, S; Franzblau, SG; Markley, LD; Miller, MJ; Moraski, GC; Oliver, AG	1
Achar, V; Ambady, A; Awasthy, D; Bandodkar, B; Bellale, E; Chatterji, M; Guptha, S; Kaur, P; McLaughlin, R; Morayya, S; Naik, M; Narayan, A; Panda, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Sharma, S; V B, V; Vachaspati, P; Whiteaker, J	1
Hameed P, S; Kaur, P; Madhavapeddi, P; Menasinakai, S; Nandishaiah, R; Panduga, V; Raichurkar, A; Reddy, J; Sambandamurthy, VK; Sharma, S; Sriram, D	1
Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M	1
Balakrishnan, G; Bhat, J; Chatterji, M; Dinesh, N; Ghorpade, S; Gorai, G; Guptha, S; Humnabadkar, V; Iyer, PS; Jena, LK; Kaur, P; Khadtare, P; Naik, M; Nandishaiah, R; Narayan, A; Naviri, LK; Panda, M; Ramachandran, V; Sharma, S	1
Devi, PB; Samala, G; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P	1
Kulkarni, P; Medapi, B; Medishetti, R; Renuka, J; Saxena, S; Sridevi, JP; Sriram, D; Yogeeswari, P	1
Chinnapattu, M; Hameed P, S; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Nandishaiah, R; Patil, V; Puttur, J; Raichurkar, A; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Shinde, V; Solapure, S; Sriram, D	1
Medapi, B; Renuka, J; Sridevi, JP; Sriram, D; Suryadevara, P; Yogeeswari, P	1
Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R	1
Kulkarni, P; Meda, N; Medapi, B; Sriram, D; Yogeeswari, P	1
Devi, PB; Meda, N; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J	1
Daletos, G; Ebrahim, W; El-Neketi, M; Kalscheuer, R; Lewald, LI; Lin, W; Orfali, RS; Proksch, P; Rehberg, N	1
Lynch, AS; Ma, Z	1
Bobesh, KA; Gunda, S; Jeankumar, VU; Reshma, RS; Saxena, S; Sriram, D; Yogeeswari, P	1
Brindha Devi, P; Gunda, S; Samala, G; Saxena, S; Sriram, D; Yogeeswari, P	1
Abbadi, BL; Back, DF; Basso, LA; Campos, MM; Giacobbo, BC; Grams, ES; Machado, P; Pissinate, K; Rodrigues-Junior, V; Santos, DS; Sperotto, N; Subtil, FT; Trindade, RV; Villela, AD	1
Bobesh, KA; Jeankumar, VU; Kapoor, N; Kolattukudy, PE; Reshma, RS; Saxena, S; Sriram, D; Vachaspathy, AR	1
Domalaon, R; Gorityala, BK; Goswami, S; Idowu, T; Lyu, Y; Schweizer, F; Shan, A; Yang, X; Zhanel, GG	1
Bosquesi, PL; Chegaev, K; Cho, SH; Chorilli, M; da Silva, PB; de Carvalho, LPS; de Souza Costa, CA; de Souza, PC; Dos Santos Fernandes, GF; Dos Santos, JL; Franzblau, SG; Fruttero, R; Guglielmo, S; Hunt, DM; Lazzarato, L; Man Chin, C; Marino, LB; Moreno-Viguri, E; Paucar, R; Pavan, FR; Pérez-Silanes, S; Ribeiro, CM; Santivañez-Veliz, M; Silva, CSP; Solcia, MC; Wang, Y	1
Malapati, P; Meda, N; Nallangi, R; Reshma Srilakshmi, R; Siva Krishna, V; Sriram, D	1
Bonnet, M; Cooper, CB; Denny, WA; Franzblau, SG; Lee, HH; Thompson, AM; Wan, B; Wong, GS	1
Krishna, VS; Malapati, P; Nallangi, R; Srilakshmi, RR; Sriram, D	1
Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ	1
Cleghorn, LAT; Davis, S; Epemolu, O; Ferguson, L; Green, SR; Guijarro, L; Hipskind, P; Huggett, M; Korkegian, A; Kumar, A; Lopez Moure, A; Masquelin, T; Odingo, J; Parish, T; Ray, PC; Read, KD; Riley, J; Rullas, J; Scullion, P; Shishikura, Y; Smith, A; Turner, P; Wescott, H; Wilson, C; Wyatt, PG; Zuccotto, F	1
Franzblau, SG; Hu, X; Liu, Z; Lu, X; Wan, B; Wang, R; You, Q; Zhang, T	1
Charrier, C; Cooper, IR; Kerr, WJ; Lindsay, DM; Maclean, J; McGarry, DH; Moyo, E; Pichowicz, M; Ratcliffe, AJ; Salisbury, AM; Savage, VJ; Smith, A; Stokes, NR; Walker, R; Warrilow, CE	1
Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S	1
Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ	1
da Silva Emery, F; de Melo, SMG; Fumagalli, F; Pavan, FR; Ribeiro, CM; Solcia, MC	1
Bishai, WR; Duan, G; Gunosewoyo, H; Liu, LL; Lun, S; Tang, J; Xiao, S; Yang, F; Yu, LF; Zhang, W	1
Chen, L; Chen, Z; Fan, Y; Gao, F; Lu, G; Ma, L	1
Bangalore, PK; Bollikanda, RK; Choudante, PC; Kantevari, S; Misra, S; Sridhar, B; Sriram, D; Vagolu, SK; Veeragoni, DK	1
Krishna, VS; Sirim, MM; Sriram, D; Unsal Tan, O	1
George, SE; Guddat, LW; Krishna, VS; Nallangi, R; Rekha, EM; Sai Prasad, DV; Sriram, D; Zheng, S	1
Begum, N; Bhakta, S; Castagnolo, D; Gupta, A; Kyriazi, M; Manetti, F; McHugh, TD; Pavan, FR; Ribeiro, CM; Scalacci, N; Semenya, D; Senderowitz, H; Touitou, M; Zrebna, K	1
Alonso-Rodriguez, N; Briffotaux, J; Buchieri, MV; Cimino, M; Coulibaly, S; Dallemagne, P; Gicquel, B; Lecoutey, C; Mornico, D; Ouattara, M; Rochais, C	1
Bano, G; Castagnolo, D; Chibale, K; Gianibbi, B; Manetti, F; Pavan, FR; Pisano, L; Ribeiro, CM; Semenya, D; Singh, V; Toscani, A; Touitou, M	1
Castagnolo, D; Dos Santos Fernandes, GF; Gianibbi, B; Manetti, F; Masci, D; Pavan, FR; Ribeiro, CM; Semenya, D; Touitou, M	1
Basarab, GS; Byl, JAW; Chibale, K; Engelhart, C; Eyermann, CJ; Fienberg, S; Ghorpade, SR; Govender, P; Koekemoer, L; Meshanni, J; Müller, R; Myrick, A; Osheroff, N; Reddy, V; Schnappinger, D; Singh, K; Singh, V	1
Chen, S; Ding, CZ; Franzblau, SG; Guo, F; Huang, Z; Li, L; Li, Y; Luo, W; Shen, L; Tang, D; Wang, B; Xu, D; Yang, M; Zhu, Y	1
Bin, W; Chen, S; Ding, CZ; Franzblau, SG; Hu, Y; Huang, Z; Jiang, N; Luo, W; Shen, L; Tao, X; Wei, X; Wei, Y; Xu, D; Yang, M; Zhu, Y	1
Eliopoulos, GM; Ferraro, MJ; Moellering, RC; Schülin, T; Wennersten, CB	1
Dalhoff, A; Ruckdeschel, G	1
Bottura, P; Capra, R; Maggiolo, F; Migliorino, M; Pravettoni, G; Suter, F	1
Coleman, EJ; Mandell, GL	1
Bentoucha, A; Bonnafous, P; Consigny, S; Grosset, J; Ji, B	1
Grosset, J; Ji, B	1
Cheon, SH; Dietze, R; Ellner, JJ; Hise, AG; Landen, K; Palaci, M; Phillips, M; Ribeiro, FC; Song, HY; Vinhas, S; Wallis, RS	1
Adrián, F; del Campo, R; García, C; Gómez-Lus, P; Gómez-Lus, R; Rubio, MC; Sánchez, S	1
Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A	1
Bellanova, S; Bracciale, P; Legari, G; Manisco, V; Quitadamo, M; Valerio, G	1
Bongard, E; Gillespie, SH; Gosling, RD; Kanduma, EG; Morris, RW; Nyindo, M; Sam, NE; Uiso, LO	1
Au-Yeang, C; Chan, CY; Cheng, AF; Leung, CC; Yew, WW	1
Derue, G; Frippiat, F; Meunier, F	1
García-Tapia, A; Rodríguez, JC; Royo, G; Ruiz, M	1
Almela, M; Jurado, A; Marco, F; Mensa, J; Ortega, M; Soriano, A	1
Bishai, WR; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, K	2
Bishai, WR; Grosset, JH; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, KN	1
Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Ader, F; Bernard, L; Carlier, R; Perronne, C; Salomon, J; Toubiana, J	1
Farny, K; Michault, A; Picot, S; Simac, C	1
Drobniewski, FA; Krüüner, A; Yates, MD	1
Kamel, AG; Lim, VK; Norazah, A; Rohani, MY	1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C	1
Andries, K; Chauffour, A; Jarlier, V; Lounis, N; Truffot-Pernot, C; Veziris, N	1
Chau, CH; Wong, HY; Yew, WW	1
Kubendiran, G; Mitchison, DA; Paramasivan, CN; Sulochana, S	1
Gidoh, M	1
Aarnoutse, RE; Alisjahbana, B; Burger, DM; Nijland, HM; Ruslami, R; Suroto, AJ; van Crevel, R	1
Gieffers, J; Rupp, J; Solbach, W	1
Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M	1
Allen, J; Coleman, DJ; Davies, GR; Fourie, B; Kanyok, T; Levin, J; Lienhardt, C; Mitchison, DA; Mthiyane, T; Reddy, C; Rustomjee, R; Sirgel, FA; Sturm, AW	1
Cakir, N; Kuruuzum, Z; Sezak, N; Yuce, A	1
Chauffour, A; Jarlier, V; Ji, B; Robert, J	1
Arhin, FF; Belley, A; McKay, GA; Moeck, G; Neesham-Grenon, E; Parr, TR	1
Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M	1
Chaisson, RE; Dooley, K; Dorman, SE; Flexner, C; Hackman, J; Nuermberger, E; Peloquin, CA	1
Drlica, K; Gennaro, ML; Hussain, S; Malik, M; Shi, L	1
Baietto, L; D'Avolio, A; De Rosa, FG; Di Perri, G; Garazzino, S; Patanella, S; Sciandra, M; Siccardi, M	1
Brillault, J; Couet, W; De Castro, WV; Harnois, T; Kitzis, A; Olivier, JC	1
Bishai, WR; Cezar, MC; Chaisson, RE; Chaudhary, MA; Conde, MB; De Souza, GR; Efron, A; Graça, NP; Kritski, AL; Loredo, C; Ram, M	1
Kubendiren, G; Mitchison, DA; Paramasivan, CN; Sulochana, S; Venkatesan, P	1
Gumbo, T	1
Oliver, GF; Wong, KK	1
Daley, CL	1
Fattorini, L; Filippini, P; Iona, E; Neyrolles, O; Peyron, P; Piccaro, G	1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M	1
Andries, K; Gevers, T; Lounis, N	1
Brown, DL; Drusano, GL; Eichas, A; Kulawy, R; Louie, A; Sgambati, N	1
Behillil, S; Berche, P; Coignard, H; Consigny, PH; Fraitag, S; Guet-Revillet, H; Jais, JP; Join-Lambert, O; Jullien, V; Le Guern, AS; Leflèche, A; Lortholary, O; Nassif, A; Nassif, X; Poirée, S; Ribadeau-Dumas, F; Thèze, J	1
Gieffers, J; Rupp, J; Shima, K; Solbach, W; Szaszák, M	1
DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM	1
Achawal, S; Anderson, G; Lee, WY; Ling, M; Thaker, HK	1
Brown, D; Drusano, GL; Eichas, A; Kulawy, R; Louie, A; Sgambati, N	1
Barbanti, F; Mastrantonio, P; Spigaglia, P	1
Colucci, G; Silzle, T; Solenthaler, M	1
Barry, CE; Dartois, V; Goh, A; Kern, S; Kjellsson, MC; Low, KM; Pillai, G; Via, LE; Weiner, D	1
Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE	1
Persing, DH; Tenover, FC; Tickler, IA	1
Aarnoutse, RE; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; Kremer, K; ten Kate, MT; van Soolingen, D; Verbrugh, HA	1
Balasubramanian, V; Deshpande, A; Drusano, GL; Ganguly, S; Gaonkar, S; Kumar, N; Louie, A; Mahesh Kumar, KN; Panduga, V; Reddy, J; Shandil, RK; Solapure, S; Vishwas, KG	1
Leggio, M; Podos, SD; Pucci, MJ; Thanassi, JA	1
Denti, P; Geldenhuys, H; Hanekom, W; Harrison, T; Hatherill, M; Jindani, A; McIlleron, HM; Meredith, S; Simonsson, US; van As, D; Wiesner, L; Zvada, SP	1
Fu, L; Jin, H; Li, P; Lu, Y; Mdluli, K; Upton, AM; Wang, B; Xu, J; Zhao, W; Zheng, M; Zhu, H	1
Cole, ST; Hartkoorn, RC; Lechartier, B	1
Brouwer, MC; van de Beek, D	1
Aarnoutse, RE; Achmad, TH; Apriani, L; Borm, G; Dian, S; Ganiem, AR; Ruslami, R; van Crevel, R; van der Ven, AJ	1
Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB	1
Hong, G; Jeon, K; Jeong, BH; Kim, CK; Kim, SY; Koh, WJ; Kwon, OJ; Lee, SH; Park, HY; Shin, SJ	1
Schaberg, T	1
Johnson, PD; Trevillyan, JM	1
Alcántara, F; Atwood, SS; Becerra, MC; Bonilla, CA; Mitnick, CD; Seung, KJ	1
Alland, D; Armakovitch, S; Armstrong, DT; Barry, CE; Chien, G; Cho, SN; Dorman, SE; Ellner, JJ; Joloba, ML; Lee, J; Mboowa, G; Mumbowa, F; Nakayita, G; Namaganda, C; Park, JA; Ssengooba, W; Via, LE; Yu, Y	1
Cailleaux-Cezar, M; Chaisson, RE; Conde, MB; Efron, A; Luiz, RR; Mexas, F	1
Chouiter, A; Lebowitz, D; Malinverni, R; Wolter, L; Zenklusen, C	1
Al-Ahmad, A; Ameen, H; Anderson, AC; Hellwig, E; Karygianni, L; Pelz, K; Spitzmüller, B; Wittmer, A	1
Elkington, PT; Friedland, JS; Gardiner, H; Kubler, A; Prasad, R; Singh, A; Singh, S; Singh, UK	1
Adrián Cataldi, A; Di Giulio, ÁB; Imperiale, BR; Morcillo, NS	1
Crook, AM; Gillespie, SH; McHugh, TD; Mendel, CM; Meredith, SK; Murray, SR; Nunn, AJ; Pappas, F; Phillips, PP	1
de Droogh, E; Groenen, G; Mathys, V; Soetaert, K; van de Vyvere, M	1
Cheng, J; Huo, N; Li, J; Li, Y; Lin, X; Tian, G; Wan, H; Wang, G; Wang, Y; Yang, X; Zhao, H	1
Erac, B; Ermertcan, S; Gul-Yurtsever, S; Hosgor-Limoncu, M; Ozturk, I; Yurtman, AN	1
Bateson, AL; Butcher, PD; Charalambous, S; Churchyard, GJ; Clouting, HE; Coleman, D; Geldenhuys, H; Harrison, TS; Hatherill, M; Jindani, A; Magweta, L; McHugh, TD; McIlleron, HM; Mitchison, DA; Mungofa, S; Nunn, AJ; Nyirenda, S; Phillips, PP; Shah, NA; Shepherd, J; van Dijk, JH; Zizhou, S; Zvada, SP	1
Mizrahi, V; Warner, DF	1
Aarnoutse, R; Burger, D; Dian, S; Donders, R; Ganiem, AR; Ruesen, C; Ruslami, R; Te Brake, L; van Crevel, R	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Krogfelt, KA; Nielsen, HL; Prag, J	1
Boutou, A; Chatzika, K; Kioumis, I; Kontou, P; Manika, K; Papaioannou, M; Zarogoulidis, K	1
Bettoli, V; Join-Lambert, O; Nassif, A	1
Bou-Chacra, N; Clas, SD; Gao, Y; Löbenberg, R; Roa, W; Sarfraz, M; Shi, W	1
Huang, L; Huang, Y; Liu, J; Shi, L; Xiao, H; Yu, X	1
Armstrong, DT; Barnes, GL; Cavalcante, SC; Chaisson, RE; Cohn, S; Conde, MB; Dalcolmo, M; Dooley, KE; Dorman, SE; Duarte, RS; Durovni, B; Efron, A; Loredo, C; Marzinke, MA; Mello, FC; Moulton, LH; Rolla, V; Savic, RM	1
Lu, JM; Sha, W; Xiao, HP; Yang, H; Zhang, LL; Zhang, Q	1
Darley, DR; Glanville, AR; Goeman, EE; Jensen, TO; Marriott, DJ; Shaw, K	1
Blackmore, T; McNaughton, A; McNaughton, H	1
Abratt, V; Kullin, B; Reid, SJ; Wojno, J	1
Barbanti, F; Spigaglia, P	1
Aubry, A; Chauffour, A; Jarlier, V; Robert, J; Veziris, N	1
Ajitkumar, P; Jakkala, K; Nair, RR; Pradhan, A; Sebastian, J; Swaminath, S	1
Kreiswirth, BN; Kurepina, N; Meinke, PT; Olsen, DB; Singh, SB; Xu, L; Young, K	1
Aarnoutse, R; Boeree, MJ; Charalambous, S; Churchyard, G; Colbers, A; Dawson, R; Diacon, AH; Gillespie, SH; Hanekom, M; Heinrich, N; Henne, S; Hoelscher, M; Hunt, RD; Kibiki, GS; Manyama, C; Mekota, A; Minja, LT; Mpagama, SG; Mtafya, B; Narunsky, K; Ntinginya, NE; Phillips, PPJ; Rehal, S; Reither, K; Sanne, I; Semvua, HH; van Balen, GP; Venter, A; Wallis, RS	1
Werth, BJ	1
Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N	1
Mendel, C; Murray, S; Spigelman, M	1
Babrak, L; Bermudez, LE; Burrows, G; Chinison, JJJ; Danelishvili, L; Hu, J; Morgun, A; Shulzhenko, N	1
Bori, G; Jutte, PC; Kampinga, GA; Morata, L; Nannan Panday, PV; Soriano, A; Tornero, E; Wouthuyzen-Bakker, M	1
Duarte, R; Macedo, R; Mendes-Bastos, P	1
Essack, S; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N	1
Cohen, L; Guarner, J; Hunt, WR	1
Caylá, JA; García-Goez, JF; Miro, JM; Munera, GA; Pacheco, R; Rojas, V	1
Andres, S; Beckert, P; Heyckendorf, J; Hillemann, D; Kohl, TA; Köser, CU; Lange, C; Merker, M; Moradigaravand, D; Niemann, S; Olaru, ID; Parkhill, J; Peacock, SJ; Schleusener, V; Schön, T; Sturegård, E	1
Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T	1
Arriens, S; Ford, L; Hoerauf, A; Hübner, MP; Klarmann-Schulz, U; Koschel, M; Martin, C; Pfarr, KM; Specht, S; Sternberg, S; Taylor, MJ	1
Caminero Luna, JA; Cerezo Lajas, A; de Miguel Díez, J; Rodríguez Guzmán, MDC	1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P	1
Bax, HI; de Knegt, GJ; de Steenwinkel, JEM; Mourik, BC; Simonsson, USH; Svensson, RJ; Verbon, A	1
Carrera-Pineda, R; Garcia-Luna, RC; Soto-Cabrera, E; Villamil-Osorio, LV	1
Fernandes, P; Rodriguez-Villalobos, H; Siala, W; Tulkens, PM; Van Bambeke, F	1
Astari, L; Cambau, E; do Nascimento, DC; Gillini, L; Grosset, J; Izumi, S; Kar, HK; Mieras, LF; Prakoeswa, CRS; Saunderson, PR; Scollard, DM; Smith, WCS; Sturkenboom, MGG; Taal, AT; van Brakel, WH; Virmond, MCL	1
Chojnacki, M; Dunman, PM; Philbrick, A; Reed, JN; Tomaras, A; Wozniak, RAF; Wucher, B	1
Deshpande, D; Gumbo, T; Magombedze, G; Srivastava, S	1
Chiang, CY; Conradie, F; Dalai, D; Dat, PT; Lan, N; Master, I; Mebrahtu, T; Meredith, SK; Meressa, D; Moodliar, R; Ngubane, N; Nunn, AJ; Phillips, PPJ; Rusen, ID; Sanders, K; Squire, SB; Torrea, G; Tsogt, B; van Deun, A	1
Hu, N; Qiao, Z; Wei, D; Yuan, Z; Zhang, W	1
Akkerman, OW; Alffenaar, JC; Johnson, JL; Kioumis, IP; Manika, K; Peloquin, C; Sturkenboom, MGG; Touw, DJ; van den Elsen, SHJ; van der Werf, TS	1
Arvieux, C; Dupont, M; Fily, F; Gicquel, T; Jolivet-Gougeon, A; Polard, E; Verdier, MC	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Evavold, C; Kersh, GJ; Smith, CB	1
Bozeman, L; Burman, WJ; Chaisson, RE; Chang, KC; Chen, M; Cotton, M; Dooley, KE; Dorman, SE; Engle, M; Feng, PJ; Fletcher, CV; Goldberg, SV; Ha, P; Heilig, CM; Johnson, JL; Kurbatova, EV; Lessem, E; Metchock, B; Miro, JM; Nahid, P; Nhung, NV; Pettit, AC; Phillips, PPJ; Podany, AT; Purfield, AE; Robergeau, K; Samaneka, W; Scott, NA; Sizemore, E; Swindells, S; Vernon, A; Weiner, M	1
Aubry, A; Bleibtreu, A; Fourniols, E; Funck-Brentano, C; Jaureguiberry, S; LLopis, B; Tissot, N; Zahr, N	1
Bendtsen, MAF; Bue, M; Greibe, E; Hanberg, P; Jørgensen, AR; Pedersen Jørgensen, N; Slater, J; Stilling, M; Søballe, K	1
Dai, Q; Ding, J; Xie, S; Xu, Z; Zhang, Y; Zheng, R; Zhou, Y; Zuo, W	1
Campbell, JR; Chan, ED; Gegia, M; Kwak, N; Lange, C; Lee, M; Menzies, D; Milanov, V; Winters, N; Yim, JJ	1
Adams, LB; Collins, JH; Hagge, DA; Lahiri, R; Lenz, SM; Ray, NA	1
Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M	1
Khandelwal, S; Malhotra, B; Sharma, M	1
Bryant, K; Chaisson, RE; Dooley, KE; Dorman, SE; Engle, M; Goldberg, SV; Hakim, J; Johnson, JL; Kurbatova, EV; Lourens, M; Martinson, NA; Muzanyi, G; Nahid, P; Narunsky, K; Nerette, S; Nguyen, NV; Pham, TH; Phan, HTT; Phillips, PPJ; Pierre, S; Purfield, AE; Samaneka, W; Sanne, I; Savic, RM; Scott, NA; Shenje, J; Sizemore, E; Swindells, S; Vernon, A; Waja, Z; Weiner, M	1
Mizrahi, V; Rubin, EJ	1
Ajitkumar, P; Jakkala, K; Pradhan, A; Swaminath, S	1
Draper, HR; Fourie, B; Garcia-Prats, AJ; Hesseling, AC; Nielsen, J; Radtke, KK; Savic, RM; Schaaf, HS; Solans, BP; Thee, S; van der Laan, LE; Wiesner, L; Winckler, JL	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Aarnoutse, RE; Boeree, MJ; Bolwerk, C; Burger, DM; Greupink, R; Hoefsloot, W; Koenderink, JB; Kuipers, S; Litjens, CHC; Magis-Escurra, C; Ruslami, R; Russel, FGM; Svensson, EM; Te Brake, LHM; van Crevel, R; van den Broek, PHH; van den Heuvel, JJMW; van Ingen, J; van Laarhoven, A; Verscheijden, LFM	1
Bue, M; Fichtner Bendtsen, MA; Hanberg, P; Jørgensen, AR; Jørgensen, NP; Slater, J; Stilling, M; Søballe, K	1
Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC	1
Allen, L; Carr, W; Goswami, N; Kurbatova, E; Starks, A; Winston, C	1
Akrami, S; Dokht Khosravi, A; Hashemzadeh, M	1
Abdrabou, AMM; Berger, FK; Bischoff, M; Gärtner, BC; Margardt, L; Mellmann, A; von Müller, L	1
Guo, Y; Liu, H; Sha, W; Shen, H; Shen, X; Tan, G; Wu, X; Wu, Z; Yang, J; Yu, F	1
Beraldi-Magalhães, F; Fernandez-Llimos, F; Imazu, P; Pontarolo, R; Santos, JM; Tonin, FS	1
Koesoemoprodjo, W; Kusmiati, T; Luthfah, N; Mertaniasih, NM; Putranto, JNE; Sari, AP; Soedarsono, S; Suprapti, B	1
Guo, Y; Huang, C; Sha, W; Tan, G; Wu, X; Yang, J; Yu, F	1
Lu, D; Luo, Z; Qian, J; Wang, C; Wang, T; Ye, F; Zhang, J	1
Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF	1
Bland, MJ; Gabant, P; Gala, JL; Martin, A; Rodriguez-Villalobos, H	1
Arodola-Oladoyinbo, O; Chirehwa, M; Denti, P; Gengiah, TN; Kawuma, AN; Naidoo, A; Naidoo, K; Padayatchi, N; Perumal, R	1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z	1
Al-Zubaidi, A; Cheung, CY; Cook, GM; Dawes, SS; Lott, JS; Mizrahi, V; Taiaroa, G	1
Brankin, A; Colman, RE; Georghiou, SB; Seifert, M; Suresh, A; Uplekar, S; Walker, TM	1
Chu, N; Gu, Y; Luo, H; Wang, Q; Xiao, Y; Yang, J; Zhang, J	1
Berry, C; Dodd, M; du Cros, P; Fielding, K; Kazounis, E; Liverko, I; McHugh, TD; Moodliar, R; Moore, DAJ; Motta, I; Ngubane, N; Nyang'wa, BT; Parpieva, N; Rassool, M; Ritmeijer, K; Solodovnikova, V; Spigelman, M; Tigay, Z	1
Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M	1
Bock, M; Bruun, NE; Bundgaard, H; Christensen, JJ; Christiansen, U; Elming, H; Fosbøl, EL; Fuursted, K; Gill, S; Helweg-Larsen, J; Høfsten, D; Høiby, N; Ihlemann, N; Iversen, K; Kristensen, JH; Køber, L; Lemming, L; Lerche, CJ; Moser, C; Nielsen, HL; Pedersen, CT; Povlsen, JA; Pries-Heje, MM; Rosenvinge, FS; Schultz, M; Theut, AM; Tønder, N; van Hasselt, JGC; Wang, H	1
Aubry, A; Bleibtreu, A; Coiffard, J; Fourniols, E; Junot, H	1
Chen, X; Feng, Z; Ge, S; Li, R; Li, Y; Miao, Y; Peng, Y; Song, L; Sun, F; Wang, X; Zhang, W; Zhang, Y	1
Alffenaar, JW; Aryal, S; Boorgula, GD; Dheda, K; Gumbo, T; Malinga, L; Raj, P; Shankar, P; Singh, S; Srivastava, S; Thomas, TA	1
Berge, I; Bogdanova, I; Freimane, L; Norvaiša, I; Ozere, I; Ranka, R; Sadovska, D; Vaivode, A; Vīksna, A	1
Aalhoul, F; Cotton, F; Fage, D	1
Adeel, A; Ahmad, A; Ahmad, I; Aslam, H; Mushtaq, F; Raza, SM; Saleem, S	1
Bocanegra-Ibarias, P; Camacho-Ortiz, A; Flores-Treviño, S; Perez-Alba, E; Vilchez-Cavazos, F; Villarreal-Salazar, V	1

Reviews

15 review(s) available for moxifloxacin and rifampin

Article	Year
New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:3 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Mycobacterium tuberculosis; Rifamycins; Tuberculosis	2009
Tuberculosis: the drug development pipeline at a glance. European journal of medicinal chemistry, 2012, Volume: 51 Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis	2012
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculosis	2013
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Fluoroquinolone derivatives and their anti-tubercular activities. European journal of medicinal chemistry, 2018, Feb-25, Volume: 146 Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis	2018
Fluoroquinolone-isatin hybrids and their biological activities. European journal of medicinal chemistry, 2019, Jan-15, Volume: 162 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship	2019
Update in tuberculosis 2009. American journal of respiratory and critical care medicine, 2010, Mar-15, Volume: 181, Issue:6 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Mice; Moxifloxacin; Oxazolidinones; Quinolines; Rifampin; Tuberculosis; Tuberculosis Vaccines; Vitamin D; Vitamins	2010
[Tuberculosis: new treatment options and updated recommendations]. Deutsche medizinische Wochenschrift (1946), 2013, Volume: 138, Issue:14 Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2013
Antibiotic Treatment of Hidradenitis Suppurativa. Dermatologic clinics, 2016, Volume: 34, Issue:1 Topics: Anti-Bacterial Agents; beta-Lactams; Ceftriaxone; Clindamycin; Drug Therapy, Combination; Ertapenem; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Imipenem; Maintenance Chemotherapy; Metronidazole; Moxifloxacin; Remission Induction; Rifampin	2016
A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis. Journal of clinical pharmacology, 2017, Volume: 57, Issue:11 Topics: Animals; Antitubercular Agents; Drug Interactions; Fluoroquinolones; Humans; Moxifloxacin; Rifampin; Tuberculosis	2017
Brucellar reproductive system injury: A retrospective study of 22 cases and review of the literature. The Journal of international medical research, 2020, Volume: 48, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Brucella; Brucellosis; China; Doxycycline; Drug Therapy, Combination; Female; Genitalia; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Rifampin	2020
Changes in treatment for multidrug-resistant tuberculosis according to national income. The European respiratory journal, 2020, Volume: 56, Issue:5 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant	2020
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Efficacy and safety of daily treatments for drug-susceptible pulmonary tuberculosis: a systematic review and network meta-analysis. The Journal of pharmacy and pharmacology, 2022, Jun-09, Volume: 74, Issue:6 Topics: Antitubercular Agents; Bayes Theorem; Drug Therapy, Combination; Humans; Moxifloxacin; Network Meta-Analysis; Rifampin; Tuberculosis, Pulmonary	2022
Evaluation of the Therapeutic Effect of Antibiotics on Scrub Typhus: A Systematic Review and Network Meta-Analysis. Frontiers in public health, 2022, Volume: 10 Topics: Anti-Bacterial Agents; Azithromycin; Child; Chloramphenicol; Female; Humans; Moxifloxacin; Network Meta-Analysis; Rifampin; Scrub Typhus	2022

Trials

25 trial(s) available for moxifloxacin and rifampin

Article	Year
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:8 Topics: Adult; Antitubercular Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aza Compounds; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Polymorphism, Genetic; Quinolines; Rifampin; Therapeutic Equivalency	2007
The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American journal of respiratory and critical care medicine, 2003, Dec-01, Volume: 168, Issue:11 Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Aza Compounds; Female; Fluoroquinolones; Humans; Inhibitory Concentration 50; Isoniazid; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Sputum; Tuberculosis, Pulmonary	2003
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Oct-15, Volume: 45, Issue:8 Topics: Adolescent; Adult; Antibiotics, Antitubercular; Aza Compounds; Drug Interactions; Female; Fluoroquinolones; Humans; Indonesia; Isoniazid; Male; Middle Aged; Moxifloxacin; Plasma; Quinolines; Rifampin; Tuberculosis, Pulmonary	2007
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Gatifloxacin; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Nonlinear Dynamics; Ofloxacin; Pyrazinamide; Quinolines; Rifampin; Sputum	2008
Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Adult; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Safety; Tuberculosis, Pulmonary; Young Adult	2008
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (London, England), 2009, Apr-04, Volume: 373, Issue:9670 Topics: Adult; Antitubercular Agents; Aza Compounds; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Kaplan-Meier Estimate; Logistic Models; Male; Moxifloxacin; Multivariate Analysis; Pyrazinamide; Quinolines; Rifampin; Sputum; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2009
Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8 Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2012
Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. The Lancet. Infectious diseases, 2013, Volume: 13, Issue:1 Topics: Adolescent; Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Humans; Indonesia; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Tuberculosis, Meningeal; Young Adult	2013
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adult; Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; HIV Seropositivity; Humans; Isoniazid; Kaplan-Meier Estimate; Male; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2014
Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis. International journal of antimicrobial agents, 2015, Volume: 45, Issue:5 Topics: Adolescent; Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Indonesia; Male; Middle Aged; Moxifloxacin; Plasma; Rifampin; Survival Analysis; Tuberculosis, Meningeal; Young Adult	2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PloS one, 2016, Volume: 11, Issue:5 Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2016
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet. Infectious diseases, 2017, Volume: 17, Issue:1 Topics: Adamantane; Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Ethylenediamines; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Rifampin; South Africa; Tanzania; Tuberculosis, Pulmonary	2017
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB. The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary	2017
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2019, 03-28, Volume: 380, Issue:13 Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemporary clinical trials, 2020, Volume: 90 Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combination; Equivalence Trials as Topic; Ethambutol; Female; HIV Infections; Humans; Male; Middle Aged; Moxifloxacin; Rifampin; Tuberculosis, Pulmonary; Young Adult	2020
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. The Lancet. Microbe, 2020, Volume: 1, Issue:2 Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2020
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. The New England journal of medicine, 2021, 05-06, Volume: 384, Issue:18 Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Child; Confidence Intervals; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary; Young Adult	2021
Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. Journal of clinical pharmacology, 2022, Volume: 62, Issue:3 Topics: Adult; Antitubercular Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Drug Therapy, Combination; Glucuronosyltransferase; HEK293 Cells; Humans; Models, Biological; Moxifloxacin; Multidrug Resistance-Associated Protein 2; Rifampin	2022
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4 Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis	2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3 Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary	2023
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. The New England journal of medicine, 2022, 12-22, Volume: 387, Issue:25 Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Linezolid; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2022
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial. BMC infectious diseases, 2023, May-08, Volume: 23, Issue:1 Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis	2023

Other Studies

213 other study(ies) available for moxifloxacin and rifampin

Article	Year
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:1 Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors	2007
In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Acetamides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Biofilms; DNA, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Nafcillin; Oxazolidinones; Penicillin-Binding Proteins; Penicillins; Reverse Transcriptase Polymerase Chain Reaction; Staphylococcal Infections; Staphylococcus; Tetracycline	2007
Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:3 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Drug Synergism; Female; Lung; Mice; Organ Size; Pyrazinamide; Quinolines; Spleen; Survival Analysis; Tuberculosis, Pulmonary	2007
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:4 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen	2007
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:10 Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Clarithromycin; Colony Count, Microbial; Drug Combinations; Female; Fluoroquinolones; Foot; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Quinolines; Rifampin; Streptomycin	2007
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Antimicrobial susceptibilities and clinical sources of Dialister species. Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:12 Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae	2007
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:2 Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Multigene Family; Sequence Analysis, DNA; Substrate Specificity	2008
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary	2008
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids	2008
Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Anti-Infective Agents; Biofilms; Bioreactors; Electricity; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Staphylococcus epidermidis	2009
In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:11 Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Enterocolitis, Pseudomembranous; Glycosides; Humans; In Vitro Techniques; Microbial Sensitivity Tests	2008
Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Dose-Response Relationship, Drug; Fusidic Acid; Gentamicins; Humans; Macrophages; Microbial Sensitivity Tests; Oxacillin; Phenotype; Protein Binding; Staphylococcus aureus; Thymidine	2009
Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua. Journal of natural products, 2009, May-22, Volume: 72, Issue:5 Topics: Anti-Bacterial Agents; Bacillus anthracis; Cyanobacteria; Indole Alkaloids; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular	2009
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes. Journal of medicinal chemistry, 2009, Oct-22, Volume: 52, Issue:20 Topics: Antitubercular Agents; Carboxylic Acids; Esters; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Activity Relationship	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Synthesis, antimalarial and antitubercular activity of acetylenic chalcones. Bioorganic & medicinal chemistry letters, 2010, Feb-01, Volume: 20, Issue:3 Topics: Alkynes; Antimalarials; Antitubercular Agents; Chalcones; Mycobacterium tuberculosis; Plasmodium falciparum	2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:5 Topics: Acetamides; Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Drug Discovery; Ethambutol; Fluoroquinolones; Immunocompetence; Inhalation Exposure; Isoniazid; Linezolid; Mice; Mice, Inbred C57BL; Moxifloxacin; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Rifampin; Tuberculosis, Pulmonary	2010
In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: Aminopyridines; Antitubercular Agents; Aza Compounds; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium avium Complex; Mycobacterium chelonae; Mycobacterium fortuitum; Mycobacterium Infections; Mycobacterium kansasii; Mycobacterium tuberculosis; Nontuberculous Mycobacteria; Ofloxacin; Quinolines; Rifampin; Species Specificity	2010
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:7 Topics: Anti-Bacterial Agents; Erythromycin; Luminescent Proteins; Microbial Sensitivity Tests; Models, Genetic; Mycobacterium ulcerans; Reserpine; Tetracycline	2010
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8 Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolones; Thiazoles; Topoisomerase II Inhibitors; Tuberculosis	2010
Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Biofilms; Clarithromycin; Daptomycin; Fluoroquinolones; Microscopy, Electron, Scanning; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Vancomycin	2010
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Amikacin; Antitubercular Agents; Bacterial Proteins; Capreomycin; DNA Gyrase; DNA Mutational Analysis; DNA-Directed RNA Polymerases; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; India; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Point Mutation; Polymerase Chain Reaction; Rifampin	2010
Synthesis of non-purine analogs of 6-aryl-9-benzylpurines, and their antimycobacterial activities. Compounds modified in the imidazole ring. Bioorganic & medicinal chemistry, 2010, Oct-15, Volume: 18, Issue:20 Topics: Animals; Anti-Bacterial Agents; Chlorocebus aethiops; Drug Resistance, Bacterial; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Purines; Vero Cells	2010
Novel thiolactone-isatin hybrids as potential antimalarial and antitubercular agents. Bioorganic & medicinal chemistry letters, 2011, Apr-01, Volume: 21, Issue:7 Topics: Animals; Antimalarials; Antitubercular Agents; Isatin; Lactones; Mycobacterium tuberculosis; Plasmodium falciparum; Structure-Activity Relationship	2011
Mycobacterium tuberculosis and cholinesterase inhibitors from Voacanga globosa. European journal of medicinal chemistry, 2011, Volume: 46, Issue:7 Topics: Acetylcholinesterase; Alkaloids; Animals; Antitubercular Agents; Butyrylcholinesterase; Cholinesterase Inhibitors; Electrophorus; Horses; Indole Alkaloids; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxazines; Pentacyclic Triterpenes; Plant Extracts; Plant Leaves; Spiro Compounds; Structure-Activity Relationship; Voacanga; Xanthenes	2011
Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin. Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20 Topics: Antitubercular Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Rifampin; Rifamycins; Tuberculosis	2011
Structure-based design of novel benzoxazinorifamycins with potent binding affinity to wild-type and rifampin-resistant mutant Mycobacterium tuberculosis RNA polymerases. Journal of medicinal chemistry, 2012, Apr-26, Volume: 55, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Benzoxazines; DNA-Directed RNA Polymerases; Drug Design; Drug Resistance, Bacterial; Mice; Mycobacterium tuberculosis; Rifampin; Rifamycins	2012
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives. Bioorganic & medicinal chemistry letters, 2012, Aug-01, Volume: 22, Issue:15 Topics: Anti-Infective Agents; Antitubercular Agents; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Structure-Activity Relationship	2012
Construction and functionalization of fused pyridine ring leading to novel compounds as potential antitubercular agents. Bioorganic & medicinal chemistry letters, 2012, Jul-15, Volume: 22, Issue:14 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Ligands; Models, Molecular; Molecular Structure; Pyridines; Structure-Activity Relationship; Vero Cells	2012
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosis. Journal of medicinal chemistry, 2013, Nov-14, Volume: 56, Issue:21 Topics: Bacterial Proteins; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiazoles	2013
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. Journal of medicinal chemistry, 2014, Jun-12, Volume: 57, Issue:11 Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological Availability; Chronic Disease; DNA Gyrase; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Macrophages; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Piperidines; Protein Subunits; Rats; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis, Pulmonary	2014
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. Journal of medicinal chemistry, 2014, Jun-26, Volume: 57, Issue:12 Topics: Alcohol Oxidoreductases; Amides; Animals; Antitubercular Agents; Bacterial Proteins; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Oxidoreductases; Piperidines; Protein Binding; Quinolones; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship	2014
Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15 Topics: Antitubercular Agents; Bridged Bicyclo Compounds; Dose-Response Relationship, Drug; Heterocyclic Compounds; Hydrocarbons, Aromatic; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyridines; Pyrimidines; Structure-Activity Relationship	2014
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system. Journal of medicinal chemistry, 2014, Aug-14, Volume: 57, Issue:15 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; High-Throughput Screening Assays; Humans; Mice; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Polymorphism, Single Nucleotide; Protein Kinases; Small Molecule Libraries; Structure-Activity Relationship; Thiazoles	2014
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing. ACS medicinal chemistry letters, 2014, Jul-10, Volume: 5, Issue:7 Topics:	2014
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety. European journal of medicinal chemistry, 2014, Oct-30, Volume: 86 Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship	2014
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis. ACS medicinal chemistry letters, 2014, Sep-11, Volume: 5, Issue:9 Topics:	2014
Design and development of novel Mycobacterium tuberculosis L-alanine dehydrogenase inhibitors. European journal of medicinal chemistry, 2015, Mar-06, Volume: 92 Topics: Alanine Dehydrogenase; Animals; Cell Line; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Macrophages; Mice; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2015
Design and synthesis of novel quinoline-aminopiperidine hybrid analogues as Mycobacterium tuberculosis DNA gyraseB inhibitors. Bioorganic & medicinal chemistry, 2015, May-01, Volume: 23, Issue:9 Topics: Animals; Anti-Bacterial Agents; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium smegmatis; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish	2015
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding. ACS medicinal chemistry letters, 2015, Jul-09, Volume: 6, Issue:7 Topics:	2015
4-Aminoquinoline derivatives as novel Mycobacterium tuberculosis GyrB inhibitors: Structural optimization, synthesis and biological evaluation. European journal of medicinal chemistry, 2015, Oct-20, Volume: 103 Topics: Aminoquinolines; Antitubercular Agents; DNA Gyrase; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Topoisomerase II Inhibitors	2015
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety. Bioorganic & medicinal chemistry letters, 2015, Nov-15, Volume: 25, Issue:22 Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism	2015
Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors. Bioorganic & medicinal chemistry, 2016, Feb-15, Volume: 24, Issue:4 Topics: Acridines; Animals; Antitubercular Agents; Bacterial Proteins; Cell Line; Cell Survival; Chlorobenzoates; DNA Gyrase; Dose-Response Relationship, Drug; Embryo, Nonmammalian; Ether-A-Go-Go Potassium Channels; Gene Expression; Heart Rate; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors; Zebrafish; Zebrafish Proteins	2016
Design, synthesis and biological evaluation of imidazo[2,1-b]thiazole and benzo[d]imidazo[2,1-b]thiazole derivatives as Mycobacterium tuberculosis pantothenate synthetase inhibitors. Bioorganic & medicinal chemistry, 2016, Mar-15, Volume: 24, Issue:6 Topics: Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Imidazoles; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Peptide Synthases; Structure-Activity Relationship; Thiazoles; Zebrafish	2016
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety. Bioorganic & medicinal chemistry letters, 2016, May-01, Volume: 26, Issue:9 Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes	2016
Metabolites from the Fungal Endophyte Aspergillus austroafricanus in Axenic Culture and in Fungal-Bacterial Mixed Cultures. Journal of natural products, 2016, Apr-22, Volume: 79, Issue:4 Topics: Animals; Anti-Bacterial Agents; Aspergillus; Bacillus subtilis; Mice; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Sesquiterpenes; Staphylococcus aureus; Xanthones	2016
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections. Journal of medicinal chemistry, 2016, 07-28, Volume: 59, Issue:14 Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship	2016
Design and development of new class of Mycobacterium tuberculosisl-alanine dehydrogenase inhibitors. Bioorganic & medicinal chemistry, 2016, 09-15, Volume: 24, Issue:18 Topics: Alanine Dehydrogenase; Antitubercular Agents; Carbon-13 Magnetic Resonance Spectroscopy; Crystallography, X-Ray; Drug Design; Molecular Structure; Mycobacterium tuberculosis; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship	2016
Anti-tubercular activities of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine analogues endowed with high activity toward non-replicative Mycobacterium tuberculosis. Bioorganic & medicinal chemistry, 2016, 11-01, Volume: 24, Issue:21 Topics: Alanine Dehydrogenase; Antitubercular Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Pyrimidines; Structure-Activity Relationship; Thiophenes	2016
New insights into the SAR and drug combination synergy of 2-(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis. European journal of medicinal chemistry, 2017, Jan-27, Volume: 126 Topics: Acetamides; Animals; Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Humans; Macrophages; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Quinolines; RAW 264.7 Cells; Structure-Activity Relationship	2017
Mycobacterium tuberculosis lysine-ɛ-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. Bioorganic & medicinal chemistry, 2017, 05-15, Volume: 25, Issue:10 Topics: Antitubercular Agents; Bacterial Proteins; Benzothiazoles; Binding Sites; Catalytic Domain; Drug Design; Enzyme Inhibitors; Molecular Docking Simulation; Mycobacterium tuberculosis; Structure-Activity Relationship; Transaminases	2017
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline. Journal of medicinal chemistry, 2017, 05-11, Volume: 60, Issue:9 Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hemolysis; Lysine; Microbial Sensitivity Tests; Minocycline; Models, Biological; Rifampin; Tobramycin	2017
Design, Synthesis, and Characterization of N-Oxide-Containing Heterocycles with in Vivo Sterilizing Antitubercular Activity. Journal of medicinal chemistry, 2017, 10-26, Volume: 60, Issue:20 Topics: Animals; Antitubercular Agents; Biological Availability; Caco-2 Cells; Heterocyclic Compounds; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxides; Spectrum Analysis	2017
Lead identification and optimization of bacterial glutamate racemase inhibitors. Bioorganic & medicinal chemistry, 2018, 01-01, Volume: 26, Issue:1 Topics: Amino Acid Isomerases; Animals; Antitubercular Agents; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; RAW 264.7 Cells; Structure-Activity Relationship	2018
Antitubercular Nitroimidazoles Revisited: Synthesis and Activity of the Authentic 3-Nitro Isomer of Pretomanid. ACS medicinal chemistry letters, 2017, Dec-14, Volume: 8, Issue:12 Topics:	2017
Identification and development of benzoxazole derivatives as novel bacterial glutamate racemase inhibitors. European journal of medicinal chemistry, 2018, Feb-10, Volume: 145 Topics: Amino Acid Isomerases; Animals; Anti-Bacterial Agents; Benzoxazoles; Biofilms; Cell Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Kinetics; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Molecular Structure; Mycobacterium; RAW 264.7 Cells; Structure-Activity Relationship; Zebrafish	2018
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB. Journal of medicinal chemistry, 2018, Aug-09, Volume: 61, Issue:15 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Cytochromes c; Mice; Morpholines; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiophenes; Vero Cells	2018
Benzylsulfanyl benzo-heterocycle amides and hydrazones as new agents against drug-susceptible and resistant MedChemComm, 2017, Jun-01, Volume: 8, Issue:6 Topics:	2017
Design, synthesis and antibacterial properties of pyrimido[4,5-b]indol-8-amine inhibitors of DNA gyrase. Bioorganic & medicinal chemistry letters, 2018, 09-15, Volume: 28, Issue:17 Topics: Anti-Bacterial Agents; Cell Survival; DNA Gyrase; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacteria; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors	2018
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety. Bioorganic & medicinal chemistry letters, 2019, 01-01, Volume: 29, Issue:1 Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Quinolines; Structure-Activity Relationship	2019
Exploiting the furo[2,3-b]pyridine core against multidrug-resistant Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters, 2019, 04-15, Volume: 29, Issue:8 Topics: Amination; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Furans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridines; Structure-Activity Relationship	2019
Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Coumarins; Crystallography, X-Ray; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Microbial Sensitivity Tests; Molecular Docking Simulation; Mycobacterium tuberculosis; Polyketide Synthases; Structure-Activity Relationship; Vero Cells	2019
Synthesis and biological evaluation of moxifloxacin-acetyl-1,2,3-1H-triazole-methylene-isatin hybrids as potential anti-tubercular agents against both drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. European journal of medicinal chemistry, 2019, Oct-15, Volume: 180 Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Isatin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Structure-Activity Relationship; Triazoles; Vero Cells	2019
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents. Journal of natural products, 2020, 01-24, Volume: 83, Issue:1 Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacillus subtilis; Benzofurans; Lichens; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Triazoles	2020
Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity. European journal of medicinal chemistry, 2020, Feb-15, Volume: 188 Topics: Acrylonitrile; Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2020
Design and development of ((4-methoxyphenyl)carbamoyl) (5-(5-nitrothiophen-2-yl)-1,3,4-thiadiazol-2-yl)amide analogues as Mycobacterium tuberculosis ketol-acid reductoisomerase inhibitors. European journal of medicinal chemistry, 2020, May-01, Volume: 193 Topics: Amides; Animals; Antitubercular Agents; Biofilms; Cell Line; Dose-Response Relationship, Drug; Drug Development; Enzyme Inhibitors; HEK293 Cells; Humans; Ketol-Acid Reductoisomerase; Macrophages; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship	2020
Improving the Potency of ACS medicinal chemistry letters, 2020, May-14, Volume: 11, Issue:5 Topics:	2020
Phenanthrolinic analogs of quinolones show antibacterial activity against M. tuberculosis. European journal of medicinal chemistry, 2020, Dec-01, Volume: 207 Topics: Antitubercular Agents; Drug Design; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenanthrolines; Quinolones	2020
Structural Rigidification of ACS medicinal chemistry letters, 2022, Jan-13, Volume: 13, Issue:1 Topics:	2022
Tapping into the antitubercular potential of 2,5-dimethylpyrroles: A structure-activity relationship interrogation. European journal of medicinal chemistry, 2022, Jul-05, Volume: 237 Topics: Animals; Antitubercular Agents; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrroles; Structure-Activity Relationship	2022
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. Journal of medicinal chemistry, 2022, 05-12, Volume: 65, Issue:9 Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA Gyrase; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Topoisomerase II Inhibitors	2022
Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-01, Volume: 71 Topics: Animals; Antitubercular Agents; Long QT Syndrome; Mycobacterium tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Discovery and preclinical evaluations of JBD0131, a novel nitrodihydro-imidazooxazole anti-tuberculosis agent. Bioorganic & medicinal chemistry letters, 2022, 09-15, Volume: 72 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrobial agents and chemotherapy, 1998, Volume: 42, Issue:6 Topics: Anti-Bacterial Agents; Aza Compounds; Fluoroquinolones; Humans; Ketolides; Legionella; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Rifampin	1998
The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results. The Journal of antimicrobial chemotherapy, 1999, Volume: 43 Suppl B Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Aza Compounds; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Legionella; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin	1999
In-vitro activity of moxifloxacin combined with other antibacterials against methicillin-resistant Staphylococcus aureus. Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:3 Topics: Anti-Infective Agents; Aza Compounds; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Fluoroquinolones; Gentamicins; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Staphylococcus aureus; Trimethoprim, Sulfamethoxazole Drug Combination; Vancomycin	2000
Activities of antimicrobial agents against intracellular pneumococci. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:9 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured	2000
Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrobial agents and chemotherapy, 2000, Volume: 44, Issue:10 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Female; Fluoroquinolones; Foot; Ketolides; Leprostatic Agents; Leprosy; Macrolides; Mice; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium leprae; Quinolines; Rifampin; Skin	2000
Combination of rifapentine-moxifloxacin-minocycline (PMM) for the treatment of leprosy. Leprosy review, 2000, Volume: 71 Suppl Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoroquinolones; Leprostatic Agents; Leprosy; Mice; Mice, Inbred Strains; Minocycline; Moxifloxacin; Probability; Quinolines; Rifampin; Treatment Outcome	2000
A whole blood bactericidal assay for tuberculosis. The Journal of infectious diseases, 2001, Apr-15, Volume: 183, Issue:8 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Blood; Blood Bactericidal Activity; Culture Media; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Quinolines; Rifampin	2001
Comparative in vitro bacteriostatic and bactericidal activity of trovafloxacin, levofloxacin and moxifloxacin against clinical and environmental isolates of Legionella spp. International journal of antimicrobial agents, 2001, Volume: 18, Issue:1 Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Fluoroquinolones; Humans; Legionella; Legionellosis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifampin	2001
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:12 Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Microbial; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Quinolines; Rifampin; Spleen; Streptomycin; Survival Rate; Tuberculosis	2001
Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:1 Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2003
In vitro postantibiotic effects of rifapentine, isoniazid, and moxifloxacin against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2004, Volume: 48, Issue:1 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Drug Combinations; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin	2004
Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections. The Journal of antimicrobial chemotherapy, 2004, Volume: 54, Issue:6 Topics: Anti-Bacterial Agents; Aza Compounds; Bone Diseases, Infectious; Drug Therapy, Combination; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Joint Diseases; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin	2004
Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy, 2004, Volume: 50, Issue:5 Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Structure-Activity Relationship; Time Factors	2004
[In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis]. Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2005, Volume: 18, Issue:2 Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Clindamycin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Levofloxacin; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Oxazolidinones; Quinolines; Rifampin; Staphylococcus aureus; Staphylococcus epidermidis	2005
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. American journal of respiratory and critical care medicine, 2005, Dec-01, Volume: 172, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary	2005
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. American journal of respiratory and critical care medicine, 2005, Dec-01, Volume: 172, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Follow-Up Studies; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Spleen; Treatment Outcome; Tuberculosis; Vaccines, DNA	2005
Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:10 Topics: Animals; Animals, Outbred Strains; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Random Allocation; Rifampin; Survival Rate; Time Factors; Tuberculosis	2005
[Cervical spondylodiscitis: one pathogen may hide another]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:1 Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Cervical Vertebrae; Cholecystitis; Discitis; Disease Progression; Drug Therapy, Combination; Escherichia coli; Escherichia coli Infections; Ethambutol; Fluoroquinolones; France; Humans; Immobilization; Isoniazid; Male; Middle Aged; Morocco; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Radiography; Rifampin; Tuberculosis, Spinal	2006
[Antimicrobial resistance of Streptococcus pneumoniae strains isolated in the Reunion Island during 2004]. Medecine et maladies infectieuses, 2006, Volume: 36, Issue:1 Topics: Aza Compounds; beta-Lactams; Cephalosporin Resistance; Cephalosporins; Chloramphenicol; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Ketolides; Moxifloxacin; Penicillin Resistance; Quinolines; Retrospective Studies; Reunion; Rifampin; Streptococcal Infections; Streptococcus pneumoniae; Tetracycline; Trimethoprim, Sulfamethoxazole Drug Combination	2006
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. Journal of clinical microbiology, 2006, Volume: 44, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
In-vitro activity of quinupristin/dalfopristin, levofloxacin and moxifloxacin against fusidic acid and rifampicin-resistant strains of methicillin-resistant Staphylococcus aureus (MRSA) from Malaysian hospitals. The Medical journal of Malaysia, 2005, Volume: 60, Issue:4 Topics: Anti-Bacterial Agents; Aza Compounds; Disease Susceptibility; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Fusidic Acid; Humans; In Vitro Techniques; Levofloxacin; Malaysia; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Rifampin; Staphylococcus aureus; Virginiamycin	2005
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. American journal of respiratory and critical care medicine, 2006, Jul-01, Volume: 174, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2006
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors	2006
Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:11 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Drug Combinations; Drug Resistance, Multiple, Bacterial; Ethionamide; Fluoroquinolones; Lung; Mice; Moxifloxacin; Mycobacterium tuberculosis; Organ Size; Pyrazinamide; Quinolines; Rifampin; Spleen; Survival Analysis; Tuberculosis	2006
Moxifloxacin-induced arthropathy. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2007, Volume: 11, Issue:1 Topics: Aged, 80 and over; Antitubercular Agents; Arthritis; Aza Compounds; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Tuberculosis, Pulmonary	2007
Moxifloxacin and gatifloxacin in an acid model of persistent Mycobacterium tuberculosis. Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:6 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Synergism; Fluoroquinolones; Gatifloxacin; Hydrogen-Ion Concentration; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Time Factors	2006
[In-vitro and in-vivo activities of moxifloxacin and garenoxacin against Mycobacterium leprae]. Nihon Hansenbyo Gakkai zasshi = Japanese journal of leprosy : official organ of the Japanese Leprosy Association, 2007, Volume: 76, Issue:1 Topics: Animals; Anti-Infective Agents; Aza Compounds; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Leprostatic Agents; Levofloxacin; Mice; Mice, Inbred BALB C; Mice, Nude; Moxifloxacin; Mycobacterium leprae; Ofloxacin; Quinolines; Rifampin	2007
Variation in the mutation frequency determining quinolone resistance in Chlamydia trachomatis serovars L2 and D. The Journal of antimicrobial chemotherapy, 2008, Volume: 61, Issue:1 Topics: Anti-Bacterial Agents; Aza Compounds; Chlamydia trachomatis; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Genotype; HeLa Cells; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Quinolones; Rifampin	2008
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS medicine, 2007, Volume: 4, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Secondary Prevention; Time Factors; Tuberculosis	2007
Doctors report breakthrough antibiotic treatment for TB. The AIDS reader, 2007, Volume: 17, Issue:11 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Mice; Moxifloxacin; Quinolines; Rifampin; Treatment Outcome; Tuberculosis	2007
Comparison of rifampicin and moxifloxacin efficacy in an experimental model of animal brucellosis. Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:1 Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Brucellosis; Disease Models, Animal; Fluoroquinolones; Moxifloxacin; Quinolines; Rats; Rats, Wistar; Rifampin	2008
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6 Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Clarithromycin; Colony Count, Microbial; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Quinolines; Rifampin; Treatment Outcome	2008
Assessment by time-kill methodology of the synergistic effects of oritavancin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Drug Synergism; Fluoroquinolones; Gentamicins; Glycopeptides; Humans; Linezolid; Lipoglycopeptides; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Polysorbates; Quinolines; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Surface-Active Agents; Vancomycin Resistance	2008
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? American journal of respiratory and critical care medicine, 2008, Nov-01, Volume: 178, Issue:9 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoroquinolones; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Pyrazinamide; Quinolines; Recurrence; Rifampin; Time Factors; Treatment Outcome; Tuberculosis	2008
In vitro model of mycobacterial growth arrest using nitric oxide with limited air. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:1 Topics: Air; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Mycobacterium; Nitric Oxide Donors; Quinolines; Rifampin; Triazenes	2009
Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. Therapeutic drug monitoring, 2009, Volume: 31, Issue:1 Topics: Acetamides; Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Moxifloxacin; Ofloxacin; Oxazolidinones; Quality Control; Quinolines; Reference Standards; Reproducibility of Results; Rifampin; Solutions; Solvents; Spectrophotometry, Ultraviolet	2009
P-glycoprotein-mediated transport of moxifloxacin in a Calu-3 lung epithelial cell model. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aza Compounds; Biological Transport; Cells, Cultured; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Lung; Moxifloxacin; Quinolines; Rifampin	2009
Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. Journal of chemotherapy (Florence, Italy), 2009, Volume: 21, Issue:2 Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Cells, Cultured; Drug Therapy, Combination; Fluoroquinolones; Isoniazid; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin	2009
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambutol; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2010
Simultaneous scrofuloderma and intracranial tuberculomas: a rare presentation of systemic tuberculosis. The Australasian journal of dermatology, 2010, Volume: 51, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Brain; Diagnosis, Differential; Drug Therapy, Combination; Fluoroquinolones; Humans; Isoniazid; Lichenoid Eruptions; Male; Middle Aged; Moxifloxacin; Pyrazinamide; Quinolines; Rifampin; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Cutaneous	2010
Activity of drug combinations against dormant Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:6 Topics: 3T3 Cells; Adipocytes; Amikacin; Animals; Antitubercular Agents; Aza Compounds; Capreomycin; Colony Count, Microbial; Drug Combinations; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Latent Tuberculosis; Metronidazole; Mice; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin	2010
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins	2010
Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:11 Topics: Animals; Antibiotics, Antitubercular; Aza Compounds; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tuberculosis	2010
The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. mBio, 2010, Aug-10, Volume: 1, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Drug Synergism; Fluoroquinolones; Humans; Microbial Viability; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis	2010
Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology (Basel, Switzerland), 2011, Volume: 222, Issue:1 Topics: Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Metronidazole; Middle Aged; Moxifloxacin; Prognosis; Quinolines; Recurrence; Remission Induction; Retrospective Studies; Rifampin; Treatment Outcome; Young Adult	2011
Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:5 Topics: Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aza Compounds; Azithromycin; Cell Hypoxia; Cell Line; Chlamydia trachomatis; Doxycycline; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Rifampin	2011
Torticollis in mice intravenously infected with Mycobacterium tuberculosis. Journal of the American Association for Laboratory Animal Science : JAALAS, 2011, Volume: 50, Issue:2 Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combination; Ear, Middle; Female; Fluoroquinolones; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Otitis Media; Pyrazinamide; Quinolines; Rifampin; Torticollis; Tuberculosis	2011
Isoniazid-resistant intracranial tuberculoma treated with a combination of moxifloxacin and first-line anti-tuberculosis medication. Journal of medical microbiology, 2011, Volume: 60, Issue:Pt 10 Topics: Antitubercular Agents; Aza Compounds; Biopsy; Brain; Cerebrospinal Fluid; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Histocytochemistry; Humans; Isoniazid; Magnetic Resonance Imaging; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rifampin; Tomography, X-Ray Computed; Treatment Outcome; Tuberculoma, Intracranial; Tuberculosis, Multidrug-Resistant; Young Adult	2011
Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. mBio, 2011, Volume: 2, Issue:4 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Rifampin; Selection, Genetic; Time Factors	2011
Multidrug resistance in European Clostridium difficile clinical isolates. The Journal of antimicrobial chemotherapy, 2011, Volume: 66, Issue:10 Topics: Anti-Bacterial Agents; Aza Compounds; Clindamycin; Clostridioides difficile; Clostridium Infections; DNA Transposable Elements; DNA, Ribosomal; Drug Resistance, Multiple, Bacterial; Erythromycin; Europe; Fluoroquinolones; Humans; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Quinolines; Ribosomal Proteins; Rifampin; RNA, Ribosomal, 23S; Tetracycline	2011
Pyrazinamide-induced sideroblastic anemia. American journal of hematology, 2012, Volume: 87, Issue:3 Topics: 5-Aminolevulinate Synthetase; alpha-Thalassemia; Anemia, Sideroblastic; Antitubercular Agents; Aza Compounds; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Hemolysis; Humans; Isoniazid; Middle Aged; Moxifloxacin; Peritonitis, Tuberculous; Pyrazinamide; Pyridoxine; Quinolines; Rifampin	2012
Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Biological Availability; Disease Models, Animal; Drug Administration Schedule; Female; Fluoroquinolones; Granuloma; Humans; Isoniazid; Lung; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Quinolines; Rabbits; Rifampin; Tissue Extracts; Tuberculosis, Pulmonary	2012
Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PloS one, 2012, Volume: 7, Issue:1 Topics: Animals; Antitubercular Agents; Aza Compounds; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Markov Chains; Mice; Models, Theoretical; Moxifloxacin; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Quinolines; Rifampin; Tuberculosis, Multidrug-Resistant	2012
Antimicrobial-resistant strains of Clostridium difficile from North America. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Anti-Bacterial Agents; Aza Compounds; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; North America; Quinolines; Ribotyping; Rifampin	2012
Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB. Emerging infectious diseases, 2012, Volume: 18, Issue:4 Topics: Amikacin; Antitubercular Agents; Aza Compounds; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Genotype; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Quinolines; Rifampin; Statistics, Nonparametric; Tuberculosis, Multidrug-Resistant	2012
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Aza Compounds; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary	2012
Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7 Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Biofilms; Fluoroquinolones; Linezolid; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Oxazolidinones; Quinolines; Quinolones; Rifampin; Staphylococcus; Thiazoles; Vancomycin	2012
In vitro and in vivo activity of clofazimine against Mycobacterium tuberculosis persisters. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2012, Volume: 16, Issue:8 Topics: Animals; Antitubercular Agents; Aza Compounds; Chronic Disease; Clofazimine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Isoniazid; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Time Factors; Tuberculosis, Pulmonary	2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins	2012
Intensified intravenous rifampicin in tuberculous meningitis. The Lancet. Infectious diseases, 2013, Volume: 13, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Rifampin; Tuberculosis, Meningeal	2013
Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. The Indian journal of medical research, 2012, Volume: 136, Issue:6 Topics: Adult; Area Under Curve; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Humans; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin; Tuberculosis	2012
Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:5 Topics: Aged; Anti-Bacterial Agents; Aza Compounds; Clarithromycin; Drug Resistance, Bacterial; Ethambutol; Female; Fluoroquinolones; Humans; Lung; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Rifampin; Sputum	2013
Steroids control paradoxical worsening of Mycobacterium ulcerans infection following initiation of antibiotic therapy. The Medical journal of Australia, 2013, May-06, Volume: 198, Issue:8 Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Aza Compounds; Buruli Ulcer; Debridement; Fluoroquinolones; Glucocorticoids; Humans; Male; Moxifloxacin; Mycobacterium ulcerans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prednisolone; Quinolines; Rifampin; Young Adult	2013
Salvage therapy for multidrug-resistant tuberculosis. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2014, Volume: 20, Issue:5 Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Antitubercular Agents; Capreomycin; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Male; Moxifloxacin; Mycobacterium tuberculosis; Retrospective Studies; Rifampin; Salvage Therapy; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult	2014
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:1 Topics: Antitubercular Agents; Ethambutol; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin	2014
Understanding and retention of trial-related information among participants in a clinical trial after completing the informed consent process. Clinical trials (London, England), 2014, Volume: 11, Issue:1 Topics: Adult; Antitubercular Agents; Brazil; Comprehension; Developing Countries; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Informed Consent; Male; Middle Aged; Moxifloxacin; Randomized Controlled Trials as Topic; Retention, Psychology; Rifampin; Surveys and Questionnaires; Tuberculosis, Pulmonary	2014
TB determined: tuberculous osteomyelitis. The American journal of medicine, 2014, Volume: 127, Issue:3 Topics: Antitubercular Agents; Aza Compounds; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Fluorodeoxyglucose F18; Fluoroquinolones; Humans; Lung; Magnetic Resonance Imaging; Male; Middle Aged; Moxifloxacin; Osteomyelitis; Positron-Emission Tomography; Quinolines; Radiopharmaceuticals; Rifampin; Spine; Tomography, X-Ray Computed; Tuberculosis, Osteoarticular	2014
Antibiotic resistance and capacity for biofilm formation of different bacteria isolated from endodontic infections associated with root-filled teeth. Journal of endodontics, 2014, Volume: 40, Issue:2 Topics: Actinomyces; Actinomyces viscosus; Amoxicillin; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clindamycin; Dental Pulp Diseases; Doxycycline; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Fosfomycin; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Limosilactobacillus fermentum; Moxifloxacin; Penicillin G; Penicillin Resistance; Prevotella; Propionibacterium; Rifampin; Streptococcus mutans; Tetracycline Resistance; Tooth, Nonvital; Vancomycin Resistance	2014
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8 Topics: Antitubercular Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Epithelial Cells; Fibroblasts; Fluoroquinolones; Humans; Isoenzymes; Isoniazid; Lung; Matrix Metalloproteinases; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Primary Cell Culture; Rifampin; Stromal Cells; Tuberculosis, Pulmonary	2014
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs. The Journal of antibiotics, 2014, Volume: 67, Issue:11 Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Open Reading Frames; Rifabutin; Rifampin; Sequence Analysis, DNA; Tuberculosis	2014
False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2014, Volume: 18, Issue:10 Topics: Aged; Amikacin; Amino Acid Sequence; Antibiotics, Antitubercular; Bacterial Proteins; DNA-Directed RNA Polymerases; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Fluoroquinolones; Genotype; Humans; Isoniazid; Male; Molecular Sequence Data; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Phenotype; Pyrazinamide; Rifampin; Sensitivity and Specificity; Sputum; Tuberculosis, Pulmonary	2014
Renal abscess caused by Brucella. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2014, Volume: 28 Topics: Abscess; Anti-Bacterial Agents; Brucella melitensis; Brucellosis; Drug Therapy, Combination; Fluoroquinolones; Humans; Kidney Diseases; Male; Middle Aged; Minocycline; Moxifloxacin; Rifampin	2014
In vitro effect of moxifloxacin and rifampicin on biofilm formation by clinical MRSA isolates. Bratislavske lekarske listy, 2014, Volume: 115, Issue:8 Topics: Anti-Bacterial Agents; Biofilms; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Rifampin	2014
Shortening treatment for tuberculosis--to basics. The New England journal of medicine, 2014, Oct-23, Volume: 371, Issue:17 Topics: Antitubercular Agents; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Pulmonary	2014
Helicobacter cinaedi knee infection after arthroscopy in an immunocompetent patient. BMJ case reports, 2015, Oct-06, Volume: 2015 Topics: Adult; Anti-Bacterial Agents; Arthroscopy; Fever; Fluoroquinolones; Helicobacter; Helicobacter Infections; Humans; Knee Injuries; Knee Joint; Male; Moxifloxacin; Rifampin; Species Specificity; Synovial Fluid; Treatment Outcome	2015
Rifampicin-moxifloxacin interaction in tuberculosis treatment: a real-life study. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2015, Volume: 19, Issue:11 Topics: Adult; Aged; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Fluoroquinolones; Greece; Humans; Isoniazid; Male; Middle Aged; Moxifloxacin; Outpatients; Rifampin; Tuberculosis, Pulmonary	2015
Immune response to antituberculosis drug-loaded gelatin and polyisobutyl-cyanoacrylate nanoparticles in macrophages. Therapeutic delivery, 2016, Volume: 7, Issue:4 Topics: Animals; Antitubercular Agents; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Cyanoacrylates; Cytokines; Drug Carriers; Drug Liberation; Dynamic Light Scattering; Enbucrilate; Enzyme-Linked Immunosorbent Assay; Fluoroquinolones; Gelatin; Macrophages; Mice; Microscopy, Electron, Transmission; Moxifloxacin; Nanoparticles; Rifampin; Spectrophotometry, Ultraviolet; Tuberculosis	2016
Drug-drug interactions between moxifloxacin and rifampicin based on pharmacokinetics in vivo in rats. Biomedical chromatography : BMC, 2016, Volume: 30, Issue:10 Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Caco-2 Cells; Drug Interactions; Fluoroquinolones; Humans; Limit of Detection; Male; Moxifloxacin; Rats; Rats, Sprague-Dawley; Rifampin	2016
[Determination of in vitro synergy by a checkerboard method when 3 core antimicrobial agents of the retreatment new scheme combined against MDR-MTB and XDR-MTB]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2016, Volume: 39, Issue:6 Topics: Aminosalicylic Acids; Antibiotics, Antitubercular; Drug Synergism; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Retreatment; Rifabutin; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Donor-derived tuberculosis (TB): isoniazid-resistant TB transmitted from a lung transplant donor with inadequately treated latent infection. Transplant infectious disease : an official journal of the Transplantation Society, 2016, Volume: 18, Issue:5 Topics: Adult; Allografts; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitubercular Agents; Bacteremia; Bronchoalveolar Lavage Fluid; Bronchoscopy; Cystic Fibrosis; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Immunosuppression Therapy; Isoniazid; Latent Tuberculosis; Lung Transplantation; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pseudomonas aeruginosa; Rifampin; Tissue Donors; Tuberculosis, Pulmonary	2016
Comprehensive cost of treating one patient with MDR/pre-XDR-TB in Wellington, New Zealand. The European respiratory journal, 2016, Volume: 48, Issue:4 Topics: Adult; Amikacin; Aminosalicylic Acid; Anti-Bacterial Agents; Antitubercular Agents; Bronchoscopy; Clofazimine; Depression; Drug Costs; Emigrants and Immigrants; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Health Care Costs; Humans; India; Isoniazid; Linezolid; Male; Mediastinum; Microbial Sensitivity Tests; Moxifloxacin; New Zealand; Pyrazinamide; Radiography, Thoracic; Rifampin; Schizophrenia, Paranoid; Tuberculosis, Lymph Node; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pleural; Tuberculosis, Pulmonary	2016
Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2017, Volume: 36, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Child; Child, Preschool; Clostridioides difficile; Clostridium Infections; Diarrhea; Disk Diffusion Antimicrobial Tests; Enterotoxins; Erythromycin; Female; Fluoroquinolones; Hospitals, Chronic Disease; Humans; Infant; Infant, Newborn; Male; Middle Aged; Minisatellite Repeats; Molecular Epidemiology; Moxifloxacin; Ribotyping; Rifampin; South Africa; Young Adult	2017
Characterization of Clostridium difficile PCR-ribotype 018: A problematic emerging type. Anaerobe, 2016, Volume: 42 Topics: Anti-Bacterial Agents; Antibiosis; Bacterial Adhesion; Bacterial Toxins; Caco-2 Cells; Clindamycin; Clostridioides difficile; Cross Infection; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Erythromycin; Fluoroquinolones; Hospitals; Humans; Italy; Moxifloxacin; Ribotyping; Rifampin; Virulence	2016
Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice. PLoS neglected tropical diseases, 2016, Volume: 10, Issue:10 Topics: Animals; Anti-Bacterial Agents; Buruli Ulcer; Clarithromycin; Diarylquinolines; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium ulcerans; Rifampin	2016
De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:2 Topics: Antitubercular Agents; Bacterial Proteins; DNA Gyrase; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Genome, Bacterial; Hydroxyl Radical; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Oxidative Stress; Rifampin	2017
Thiazomycin, nocathiacin and analogs show strong activity against clinical strains of drug-resistant Mycobacterium tuberculosis. The Journal of antibiotics, 2017, Volume: 70, Issue:5 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Intercellular Signaling Peptides and Proteins; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Peptides; Peptides, Cyclic; Rifampin; Solubility; Thiazoles	2017
Exploring the pharmacodynamic interactions between tedizolid and other orally bioavailable antimicrobials against Staphylococcus aureus and Staphylococcus epidermidis. The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5 Topics: Acetamides; Administration, Oral; Anti-Bacterial Agents; Drug Interactions; Fluoroquinolones; Humans; Kinetics; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Staphylococcus epidermidis; Tetrazoles; Trimethoprim, Sulfamethoxazole Drug Combination	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
Mycobacterium tuberculosis Proteome Response to Antituberculosis Compounds Reveals Metabolic "Escape" Pathways That Prolong Bacterial Survival. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:7 Topics: Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Isoniazid; Mefloquine; Moxifloxacin; Mycobacterium tuberculosis; Proteome; Proteomics; Rifampin	2017
Moxifloxacin plus rifampin as an alternative for levofloxacin plus rifampin in the treatment of a prosthetic joint infection with Staphylococcus aureus. International journal of antimicrobial agents, 2018, Volume: 51, Issue:1 Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Prosthesis-Related Infections; Retrospective Studies; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome	2018
Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis? The British journal of dermatology, 2017, Volume: 177, Issue:4 Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Clindamycin; Contraindications, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluoroquinolones; Hidradenitis Suppurativa; Humans; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant	2017
A novel presentation of Mycobacterium avium complex in a recipient of a lung transplant: a case report. Journal of medical case reports, 2017, Aug-28, Volume: 11, Issue:1 Topics: Aged; Antitubercular Agents; Ethambutol; Female; Fluoroquinolones; Graft Rejection; Humans; Immunosuppressive Agents; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Prednisone; Pulmonary Fibrosis; Rifampin; Tacrolimus; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2017
Tuberculosis in recipients of solid-organ transplants during 1995-2015 in Cali, Colombia. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017, 11-01, Volume: 21, Issue:11 Topics: Adolescent; Adult; Antitubercular Agents; Colombia; Female; Fluoroquinolones; Graft Rejection; Humans; Male; Middle Aged; Moxifloxacin; Opportunistic Infections; Organ Transplantation; Retrospective Studies; Rifampin; Risk Factors; Sputum; Transplant Recipients; Treatment Outcome; Tuberculosis; Tuberculosis, Pulmonary; Young Adult	2017
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:2 Topics: Antitubercular Agents; Bacterial Typing Techniques; Cohort Studies; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Genome, Bacterial; Genotype; Humans; Kanamycin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Phenotype; Rifampin; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2018
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data. Bioinformatics (Oxford, England), 2018, 05-15, Volume: 34, Issue:10 Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2018
Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the Litomosoides sigmodontis mouse model. PLoS neglected tropical diseases, 2018, Volume: 12, Issue:1 Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Therapy, Combination; Filariasis; Filarioidea; Fluoroquinolones; Mice; Moxifloxacin; Rifampin; Tetracyclines; Time Factors; Treatment Outcome; Wolbachia	2018
Antituberculosis Treatment in a Patient with Celiac Disease. Archivos de bronconeumologia, 2018, Volume: 54, Issue:6 Topics: Aged; Antitubercular Agents; Celiac Disease; Diarrhea; Diet, Gluten-Free; Drug Compounding; Drug Substitution; Drug Therapy, Combination; Ethambutol; Glutens; Hemoptysis; Humans; Isoniazid; Male; Metronidazole; Moxifloxacin; Pyrazinamide; Rifampin; Smoking; Tomography, X-Ray Computed; Tuberculosis, Pulmonary	2018
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions. Journal of medical microbiology, 2018, Volume: 67, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2018
Improving treatment outcome assessment in a mouse tuberculosis model. Scientific reports, 2018, 04-09, Volume: 8, Issue:1 Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Genotype; Humans; Mice; Mice, Inbred BALB C; Models, Theoretical; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Treatment Outcome; Tuberculosis	2018
[Optochiasmatic tuberculomas as a paradoxical reaction to treatment for meningeal tuberculosis]. Revista de neurologia, 2018, Apr-16, Volume: 66, Issue:8 Topics: Adult; Antitubercular Agents; Brain Infarction; Diagnostic Errors; Disease Progression; Drug Resistance, Microbial; Drug Substitution; Ethambutol; Female; Host-Pathogen Interactions; Humans; Isoniazid; Magnetic Resonance Imaging; Meningitis, Viral; Moxifloxacin; Mycobacterium tuberculosis; Neuroimaging; Optic Chiasm; Paresis; Prednisone; Pyrazinamide; Rifampin; Thalamus; Tuberculoma; Tuberculosis, Meningeal; Vision Disorders	2018
Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Anti-Bacterial Agents; Biofilms; Daptomycin; Fusidic Acid; Humans; Microbial Sensitivity Tests; Moxifloxacin; Rifampin; Staphylococcus epidermidis	2018
An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. BMC infectious diseases, 2018, Oct-05, Volume: 18, Issue:1 Topics: Anti-Bacterial Agents; Clarithromycin; Fluoroquinolones; Humans; Leprosy; Moxifloxacin; Netherlands; Post-Exposure Prophylaxis; Rifampin	2018
Development of a Broad-Spectrum Antimicrobial Combination for the Treatment of Staphylococcus aureus and Pseudomonas aeruginosa Corneal Infections. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Animals; Anti-Bacterial Agents; Cornea; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Eye Infections, Bacterial; Female; Humans; Keratitis; Mice; Mice, Inbred BALB C; Moxifloxacin; Ophthalmic Solutions; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome; Trimethoprim	2019
Efficacy Versus Hepatotoxicity of High-dose Rifampin, Pyrazinamide, and Moxifloxacin to Shorten Tuberculosis Therapy Duration: There Is Still Fight in the Old Warriors Yet! Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2018, 11-28, Volume: 67, Issue:suppl_3 Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Humans; Liver; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Time Factors; Tuberculosis	2018
Preparation, in vitro release and antibacterial activity evaluation of rifampicin and moxifloxacin-loaded poly(D,L-lactide-co-glycolide) microspheres. Artificial cells, nanomedicine, and biotechnology, 2019, Volume: 47, Issue:1 Topics: Animals; Anti-Bacterial Agents; Biofilms; Drug Carriers; Drug Liberation; Humans; Microspheres; Moxifloxacin; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rifampin; Sheep; Staphylococcus aureus	2019
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Adult; Antitubercular Agents; Area Under Curve; Bayes Theorem; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Linear Models; Male; Middle Aged; Moxifloxacin; Reproducibility of Results; Rifampin; Tuberculosis	2019
Moxifloxacin-rifampicin combination for the treatment of non-staphylococcal Gram-positive orthopedic implant-related infections. Medecine et maladies infectieuses, 2019, Volume: 49, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Combinations; Enterococcus faecalis; Female; Gram-Positive Bacterial Infections; Hip Prosthesis; Humans; Male; Middle Aged; Moxifloxacin; Propionibacteriaceae; Prosthesis-Related Infections; Retrospective Studies; Rifampin; Streptococcal Infections; Treatment Outcome	2019
The Effect of pH on Antibiotic Efficacy against Coxiella burnetii in Axenic Media. Scientific reports, 2019, 12-02, Volume: 9, Issue:1 Topics: Anti-Bacterial Agents; Axenic Culture; Coxiella burnetii; Culture Media; Doxycycline; Hydrogen-Ion Concentration; Hydroxychloroquine; Microbial Sensitivity Tests; Moxifloxacin; Rifampin	2019
Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections. Journal of pharmaceutical and biomedical analysis, 2020, May-10, Volume: 183 Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Monitoring; Female; Humans; Levofloxacin; Limit of Detection; Male; Middle Aged; Moxifloxacin; Plasma; Reproducibility of Results; Rifampin; Tandem Mass Spectrometry	2020
Effects of rifampicin on moxifloxacin concentrations in porcine cervical spine: a randomized microdialysis study. The Journal of antimicrobial chemotherapy, 2020, 08-01, Volume: 75, Issue:8 Topics: Animals; Cervical Vertebrae; Female; Fluoroquinolones; Microdialysis; Moxifloxacin; Plasma; Rifampin; Swine	2020
Post-exposure prophylaxis (PEP) efficacy of rifampin, rifapentine, moxifloxacin, minocycline, and clarithromycin in a susceptible-subclinical model of leprosy. PLoS neglected tropical diseases, 2020, Volume: 14, Issue:9 Topics: Animals; Asymptomatic Infections; Bacterial Load; Clarithromycin; Drug Combinations; Leprostatic Agents; Leprosy; Mice; Mice, Nude; Minocycline; Moxifloxacin; Mycobacterium leprae; Post-Exposure Prophylaxis; Rifampin	2020
Drug susceptibiity testing of nontuberculous mycobacteria by broth microdilution method. Indian journal of medical microbiology, 2021, Volume: 39, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Clarithromycin; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin	2021
Shortening the Short Course of Tuberculosis Treatment. The New England journal of medicine, 2021, 05-06, Volume: 384, Issue:18 Topics: Humans; Moxifloxacin; Rifampin; Tuberculosis	2021
A method for the enrichment, isolation and validation of Mycobacterium smegmatis population surviving in the presence of bactericidal concentrations of rifampicin and moxifloxacin. FEMS microbiology letters, 2021, 07-20, Volume: 368, Issue:14 Topics: Antitubercular Agents; Bacteriological Techniques; Drug Tolerance; Gene Expression Profiling; Humans; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Reproducibility of Results; Rifampin	2021
Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 04-28, Volume: 74, Issue:8 Topics: Adult; Child; Child, Preschool; Electrocardiography; Fluoroquinolones; HIV Infections; Humans; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Moxifloxacin Concentrations in the Knee Joint, Tibial Bone, and Soft Tissue When Combined with Rifampicin: A Randomized Porcine Microdialysis Study. The Journal of bone and joint surgery. American volume, 2022, 01-05, Volume: 104, Issue:1 Topics: Administration, Oral; Animals; Area Under Curve; Drug Therapy, Combination; Female; Knee Joint; Microdialysis; Moxifloxacin; Prosthesis-Related Infections; Rifampin; Subcutaneous Tissue; Swine; Tibia	2022
Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022. MMWR. Morbidity and mortality weekly report, 2022, Feb-25, Volume: 71, Issue:8 Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis, Pulmonary; United States	2022
Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. Pathogens and global health, 2023, Volume: 117, Issue:1 Topics: Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Multiple, Bacterial; Humans; Iran; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin; Tuberculosis	2023
Implementation of a Clostridioides difficile sentinel surveillance system in Germany: First insights for 2019-2021. Anaerobe, 2022, Volume: 77 Topics: Anti-Bacterial Agents; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cross Infection; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; Moxifloxacin; Multilocus Sequence Typing; Ribotyping; Rifampin; Sentinel Surveillance	2022
Use of Whole-Genome Sequencing to Predict Microbiology spectrum, 2022, 04-27, Volume: 10, Issue:2 Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Drug Resistance; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin; Streptomycin; Tuberculosis, Multidrug-Resistant	2022
Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens. Acta medica Indonesiana, 2022, Volume: 54, Issue:1 Topics: Antitubercular Agents; C-Reactive Protein; Cytokines; Electrocardiography; Humans; Interleukin-6; Long QT Syndrome; Moxifloxacin; Rifampin; Tuberculosis, Multidrug-Resistant; Tumor Necrosis Factor-alpha	2022
Prediction of Mycobacterium tuberculosis drug resistance by nucleotide MALDI-TOF-MS. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022, Volume: 121 Topics: Amikacin; Antitubercular Agents; China; Drug Resistance; Ethambutol; Humans; Isoniazid; Kanamycin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nucleotides; Ofloxacin; Rifampin; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Streptomycin; Tuberculosis, Lymph Node	2022
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates. Translational vision science & technology, 2022, 05-02, Volume: 11, Issue:5 Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim	2022
Promising Antimicrobial Activity and Synergy of Bacteriocins Against Microbial drug resistance (Larchmont, N.Y.), 2023, Volume: 29, Issue:5 Topics: Antitubercular Agents; Bacteriocins; Drug Synergism; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Rifampin	2023
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 08-01, Volume: 26, Issue:8 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazinamide; Rifampin; South Africa; Tuberculosis	2022
RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria. Antimicrobial agents and chemotherapy, 2022, 10-18, Volume: 66, Issue:10 Topics: Anti-Bacterial Agents; Antitubercular Agents; Cell Death; Humans; Isoniazid; Moxifloxacin; Mycobacterium Infections; Mycobacterium tuberculosis; Rifampin; RNA; Streptomycin; Tuberculosis, Multidrug-Resistant	2022
In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. Scientific reports, 2022, 10-22, Volume: 12, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Genotype; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization	2022
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities. Alternative therapies in health and medicine, 2023, Volume: 29, Issue:2 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; East Asian People; Female; Gentamicins; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Moxifloxacin; Rifampin	2023
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. mBio, 2023, 04-25, Volume: 14, Issue:2 Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxifloxacin; Pyrazinamide; Rifampin; Tuberculosis	2023
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 07-26, Volume: 77, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Dicloxacillin; Endocarditis; Endocarditis, Bacterial; Humans; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Rifampin	2023
Impact of clinical pharmacist interventions in a bone and joint infection orthoseptic surgery unit. Annales pharmaceutiques francaises, 2023, Volume: 81, Issue:5 Topics: Anti-Bacterial Agents; Humans; Middle Aged; Moxifloxacin; Pharmacists; Pharmacy Service, Hospital; Retrospective Studies; Rifampin	2023
Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; beta-Lactamase Inhibitors; Humans; Isoniazid; Linezolid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis, Multidrug-Resistant	2023
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia. BMC infectious diseases, 2023, Sep-28, Volume: 23, Issue:1 Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethionamide; Humans; Isoniazid; Kanamycin; Latvia; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2023
Protein binding investigation of first-line and second-line antituberculosis drugs. International journal of antimicrobial agents, 2023, Volume: 62, Issue:6 Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein Binding; Pyrazinamide; Rifampin; Tuberculosis	2023
Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure. PloS one, 2023, Volume: 18, Issue:10 Topics: Amikacin; Antitubercular Agents; Humans; Isoniazid; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant; Verapamil	2023
Planktonic and biofilm states of Staphylococcus aureus isolated from bone and joint infections and the in vitro effect of orally available antibiotics. Journal of applied microbiology, 2023, Dec-01, Volume: 134, Issue:12 Topics: Anti-Bacterial Agents; Biofilms; Doxycycline; Humans; Microbial Sensitivity Tests; Moxifloxacin; Plankton; Rifampin; Staphylococcal Infections; Staphylococcus aureus	2023